Risk factors
Prothena Corp. Public (PRTA) risk factors
Item 1A of every Prothena Corp. Public Ltd. Co. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors61 risks3 new5 dropped11 reworded
Prothena highlights increased compliance scrutiny regarding global healthcare and anti-bribery laws across its operations.
Filed Feb 27, 2026 - FY2024 10-K risk factors63 risks
Prothena faces substantial ongoing net losses with an accumulated deficit of $1.1 billion as of December 31, 2024. Operations heavily rely on key partnerships with Roche, BMS, and Rentschler for drug development and manufacturing. Pipeline programs span multiple clinical phases for candidates including birtamimab, prasinezumab, and PRX012.
Filed Feb 27, 2025